12/23/2008 | SS | Barr ceases trading following acquisition by Teva
|
12/19/2008 | SS | Teva, Barr merger on track to close Tuesday following latest approvals
|
11/25/2008 | SS | Watson Pharmaceuticals to acquire generic products following merger of Teva, Barr
|
11/21/2008 | SS | Barr Pharmaceuticals shareholders say 'yes' to deal with Teva
|
10/28/2008 | SS | Market Commentary: Banks try to bail on Huntsman-Hexion; Teva keeps financing facilities; banks still stingy with credit
|
10/27/2008 | BKSS | Barr Pharmaceuticals amends credit facilities ahead of merger with Teva
|
9/3/2008 | SS | Teva, Barr respond to second request from FTC
|
7/18/2008 | EMIG | Teva acquires Barr, plans tapping of long-term debt market
|
7/18/2008 | IG | S&P keeps Barr on watch
|
7/18/2008 | SS | Teva to acquire Barr for $7.46 billion and $1.5 billion in debt
|
7/18/2008 | SS | Market Commentary: Yahoo!-Microsoft saga takes another turn as Legg Mason backs Yahoo! board
|
6/23/2008 | BK | Barr gets $300 million unsecured term loan
|
5/9/2008 | IG | S&P puts Barr on watch
|
11/8/2006 | BT | Barr Pharmaceuticals: contraceptive products drive growth, quarterly revenues rise to $332 million
|
10/9/2006 | BT | Jefferies: CollaGenex, Forest Labs beat Q3 estimates; Connetics lags behind
|
9/26/2006 | BT | Savient files patent infringement lawsuit against Barr
|
9/26/2006 | BT | Warner Chilcott waives exclusivity; Barr to market generic Ovcon
|
9/21/2006 | BKBTCVHY | Moody's revises ratings for nine U.S. pharma companies
|
9/18/2006 | BT | Actavis: No immediate plans to increase offer for Pliva
|
9/12/2006 | BT | S&P: Barr Pharmaceuticals unchanged
|
9/11/2006 | BT | Barr increases offer for Pliva
|
8/31/2006 | BT | Actavis raises offer for Pliva to HRK 795 per share in cash
|
8/25/2006 | BKBT | Moody's rates Barr Laboratories loan Ba1
|
8/24/2006 | BT | Barr's Duramed subsidiary gets FDA approval for over-the-counter emergency contraceptive
|
8/16/2006 | BT | S&P rates Barr loans BBB, BBB-
|
8/15/2006 | BT | Barr and its Duramed subsidiary settle Adderall litigation with Shire, sign additional agreements
|
8/15/2006 | BT | Barr reports fiscal year net earnings up at $336.5 million, generic sales increase 17% for fourth quarter
|
8/15/2006 | BT | Market Commentary: Acadia gains; Shire, Barr, New River up on settlement; Novavax rises; Vasogen off
|
8/1/2006 | BT | Barr to market generic Xanax
|
7/26/2006 | BT | Barr Pharmaceuticals gets $2.8 billion credit facility
|
7/14/2006 | BT | Barr's Duramed unit to develop Al-Sense amniotic fluid detection product with Common Sense
|
7/6/2006 | BT | Barr sued over Razadyne ER capsules
|
6/30/2006 | BT | Barr Pharmaceuticals increases tender offer for Pliva shares to $2.3 billion
|
6/30/2006 | BT | Market Commentary: Vertex soars 15% on J&J deal; Cephalon climbs over 10% on Fentora nod; Barr off slightly
|
6/29/2006 | BT | Cephalon gets approvable letter for Fentora to manage breakthrough pain
|
6/27/2006 | BT | Barr Pharmaceuticals to make $2.2 billion tender offer for Pliva shares
|
6/12/2006 | BT | Barr settles Warfarin sodium case for $22.5 million
|
5/25/2006 | BT | FDA grants approval for Barr, Duramed's Seasonique extended-cycle oral contraceptive
|
5/12/2006 | BT | Barr's acne medicine Isotretinoin approved in 30 mg strength
|
5/12/2006 | BT | Market Commentary: HemaCare's stock plummets on first quarter earnings; ChondroGene prices C$20 million PIPE
|
5/12/2006 | BT | Barr's request for Seasonale patent rejected
|
5/11/2006 | BT | Barr challenging patents protecting Prozac Weekly
|
5/4/2006 | BT | Barr to challenge Aventis' Nasacort patent
|
4/6/2006 | BT | Barr's Duramed withdraws NDA for extended-cycle oral contraceptive
|
3/17/2006 | BT | Barr gets closer to approval of Seasonique extended-cycle oral contraceptive
|
2/10/2006 | BT | Market Commentary: Acorda shares close up 12%; Shire better, other ADHD names off on drug labeling; Pfizer slides
|
2/8/2006 | BT | Citigroup reiterates Barr at hold/high risk
|
2/1/2006 | BT | Cephalon settles patent litigation with Barr over Provigil generic
|
1/27/2006 | BT | Court ruling allows Barr, Teva to market generic allergy medication
|
12/23/2005 | BT | Mylan, Barr get final FDA approval for Zonisamide, generic of Zonegran to treat epilepsy
|
12/19/2005 | BT | Market Commentary: Pfizer, other Big Pharmas zoom; generic names Barr, Teva plunge; Cubist, Rigel, Xoma, Lexicon off
|
12/2/2005 | BT | Savient, Barr settle patent litigation; Barr gets rights to birth control pill Mircette for $13.75 million
|
11/3/2005 | BT | Barr Pharmaceuticals board extends stock repurchase program through end of 2006
|
10/20/2005 | BT | Market Commentary: Predix IPO put on hold; Amgen spiral continues; Abgenix climbs; generics off despite Tamiflu talks
|
10/20/2005 | BT | Shire files Adderall patent suit against Barr, Impax Laboratories
|
10/18/2005 | BT | Duramed to acquire FEI Women's Health, ParaGard IUD
|
9/6/2005 | BT | Market Commentary: Chiron rises on rejection of bid from Novartis; Barr, Teva gain; New River higher; Andrx falls
|
9/2/2005 | BT | Market Commentary: Cell Therapeutics plunges on auditor departure; Amylin shares off on profit taking; Watson off
|
8/24/2005 | BT | Market Commentary: Shire rises on Adderall news; New River retraces gain; Barr declines; Genaera gains; Oscient Pharma off
|